Chapter 1 · Cardiovascular Medicine · Lesson 7
Valvular heart disease and rheumatic heart disease
Fellowship-level theory for the RACGP AKT and KFP, built on the 2025 Australian ARF/RHD guideline and the 2025 ESC/EACTS valvular heart disease guideline.
Two guidelines changed in 2025. The Australian guideline for acute rheumatic fever (ARF) and rheumatic heart disease (RHD), 2025 (3.2 edition) integrates the World Heart Federation 2023 echo criteria and RHD staging, updates the duration of secondary prophylaxis, and makes azithromycin a first-line oral option for sore throat in high-risk people.2 The 2025 ESC/EACTS valvular heart disease guideline lowers the age at which TAVI is preferred to 70 years and allows intervention in selected asymptomatic patients with severe aortic stenosis.1,8 There is no Australian valve disease guideline; Australian Heart Teams follow these recommendations within Medicare rules.
- 2025: ARF/RHD guideline: WHF 2023 echo criteria and RHD stages A–D; revised prophylaxis durations; azithromycin first-line oral for sore throat; empirical treatment of sore throat in high-risk young people; advanced conduction abnormalities as a minor Jones criterion.2
- Aug 2025: ESC/EACTS guideline: TAVI preferred from age 70 (previously 75); intervention may be considered in asymptomatic severe high-gradient aortic stenosis at low procedural risk.1,8
- 2022: INVICTUS trial: in rheumatic heart disease with AF, rivaroxaban was inferior to warfarin.4
Each statement below was standard teaching a few years ago. Decide whether it is still true before you tap.
TAVI is for patients aged over 75 or unfit for surgery.
A DOAC is a reasonable choice for AF in rheumatic mitral stenosis.
Secondary prophylaxis for rheumatic fever can stop at age 21 for everyone.
Cold-start check
Answer these questions before you read the lesson. Getting some wrong is the point: attempting questions before studying helps you remember the answers afterwards, and your score tells you where to spend your time.
1. Which echo finding defines severe aortic stenosis?
Valve area <1.0 cm² (with peak velocity ≥4 m/s and mean gradient ≥40 mmHg in high-gradient AS). Read 3.1 Causes and severity →
2. In the 2025 ESC/EACTS guideline, TAVI is preferred over surgery from what age?
70 (previously 75), as a Heart Team decision. Read 3.3 TAVI or surgery →
3. A patient with a mechanical heart valve asks to switch from warfarin to a DOAC. The answer is:
No. DOACs are contraindicated with mechanical valves (and with rheumatic mitral stenosis). Read 8.2 Anticoagulation →
4. How often is benzathine benzylpenicillin G (BPG) usually given for secondary prophylaxis?
Every 28 days (every 21 days for selected people, e.g. breakthrough ARF despite full adherence). Read 9.3 Secondary prophylaxis →
5. For ARF diagnosis in a high-risk population, what temperature counts as the fever criterion?
≥38°C in high-risk groups (≥38.5°C in low-risk groups). Read 9.1 Diagnosing ARF →
Your score: / 5
| Score | What to do |
|---|---|
| 5 / 5 | Strong start. Skim the key takeaways, then go straight to the self-check questions. |
| 3–4 / 5 | Read the sections linked from the questions you missed, then do the self-check. |
| 0–2 / 5 | Work through the whole lesson. Check the old-notes box above as well. |
Learning objectives
- Distinguish innocent from pathological murmurs and use bedside manoeuvres.
- Recognise, grade and refer aortic stenosis and the other main valve lesions.
- Manage anticoagulation and other care of patients with prosthetic valves.
- Diagnose acute rheumatic fever with the Australian Jones criteria.
- Deliver secondary prophylaxis and primary prevention of rheumatic fever.
How this is examined
- AKT: murmur features and manoeuvres, AS severity and symptoms, INR targets, DOAC contraindications, Jones criteria, BPG dose and interval, prophylaxis duration.
- KFP: a murmur in a child or an older patient, a febrile child with arthritis in a remote community, managing a patient on warfarin with a mechanical valve.
- Common trap: calling severe AS “stable” because symptoms are attributed to age; using a DOAC; using low-risk Jones criteria for high-risk patients.
Every section carries a GP Institute study-priority rating. It is our editorial judgement, based on the RACGP curriculum, how heavily current Australian guidelines emphasise the topic, patient safety, recent changes, and the themes in published RACGP exam reports. It is not an official RACGP weighting, and any topic can be examined.
| Rating | What it means for your study |
|---|---|
| ★★★★ | Must know. Core, frequently examined, safety-critical or recently changed. Know it cold, without notes. |
| ★★★☆ | High yield. Commonly tested; know the thresholds, drugs and next steps. |
| ★★☆☆ | Know the principles. Understand the reasoning; detailed numbers are less likely to be asked. |
| ★☆☆☆ | Background. Read once for context. |
1. Why it matters ★☆☆☆
Valvular heart disease in Australia has two faces. In older Australians, degenerative disease dominates: calcific aortic stenosis and degenerative mitral regurgitation, both increasingly common as the population ages and both often missed because symptoms are attributed to age. In Aboriginal and Torres Strait Islander communities, and in migrants from countries where it remains endemic, rheumatic heart disease affects children and young adults, especially women of child-bearing age. First Nations Australians have ARF rates nearly 100 times, and RHD rates about 50 times, those of non-Indigenous Australians.2
The GP finds the murmur, decides whether it matters, arranges echocardiography, follows patients through years of surveillance, manages anticoagulation, and in RHD delivers the monthly injections that prevent further valve damage. RHD is preventable at every stage, and primary care is where the prevention happens.
2. Assessing a murmur ★★★☆
2.1 Innocent or pathological? ★★★★
Most murmurs in children and many in pregnancy are innocent flow murmurs. In adults, especially older adults, a new murmur needs echocardiography unless it is clearly innocent. The features below help decide.
| Feature | Suggests innocent | Suggests pathological (echo) |
|---|---|---|
| Timing | Systolic (early to mid) | Any diastolic murmur; pansystolic; continuous (except venous hum) |
| Intensity | Grade ≤2/6 | Grade ≥3/6 or a thrill |
| Quality | Soft, vibratory or musical (Still’s murmur) | Harsh |
| Posture | Changes or disappears lying versus sitting | Fixed |
| Heart sounds | Normal, physiologically split S2 | Abnormal S2 (single, fixed split), clicks, S3/S4 in older people |
| Context | Well child; fever, anaemia or pregnancy (flow) | Symptoms (breathlessness, chest pain, syncope, poor feeding or growth), abnormal pulses, cyanosis, ECG abnormality, family history, high-risk population for RHD |
In an Aboriginal or Torres Strait Islander child or young person, or a migrant from an RHD-endemic country, any murmur needs echocardiography: early RHD is often clinically silent and is the window for prophylaxis.2
↔ Swipe sideways to see the whole figure
2.2 Bedside manoeuvres ★★★☆
| Manoeuvre | Physiology | Most murmurs (AS, MR, AR) | HCM and mitral valve prolapse |
|---|---|---|---|
| Valsalva strain, standing | Reduced preload | Softer | HCM louder; MVP click earlier, murmur longer |
| Squatting, leg raise | Increased preload (and afterload with squatting) | Louder | HCM softer; MVP murmur shorter |
| Handgrip | Increased afterload | MR and AR louder; AS softer | HCM softer |
| Inspiration | More venous return to the right heart | Right-sided murmurs louder (Carvallo’s sign in TR) | — |
3. Aortic stenosis ★★★★
3.1 Causes and severity ★★★☆
Calcific (degenerative) aortic stenosis is the most common valve disease needing intervention in older people. A bicuspid valve causes stenosis about a decade or two earlier, and rheumatic disease (usually with mitral involvement) is the cause in younger First Nations patients. Signs: an ejection systolic murmur at the right upper sternal edge radiating to the carotids, a slow-rising, low-volume pulse, a soft or absent A2 and a heaving apex. The murmur is often quieter when stenosis is very severe and output falls.
| Severity | Peak velocity | Mean gradient | Valve area | Usual surveillance echo |
|---|---|---|---|---|
| Aortic sclerosis | ≤2.5 m/s | — | Normal | Clinical review; echo if symptoms or murmur change |
| Mild | 2.6–2.9 m/s | <20 mmHg | >1.5 cm² | Every 3–5 years |
| Moderate | 3.0–3.9 m/s | 20–39 mmHg | 1.0–1.5 cm² | Every 1–2 years |
| Severe | ≥4.0 m/s | ≥40 mmHg | <1.0 cm² | Every 6–12 months if no intervention; cardiology |
Thresholds and intervals from ESC and ACC/AHA guidelines.1,9 “Low-flow, low-gradient” severe AS (small valve area but low gradient because of poor LV function or a small ventricle) needs specialist assessment.
3.2 Symptoms and GP management ★★★★
The classic symptoms are exertional breathlessness, angina and exertional syncope or presyncope. Once they appear in severe AS, prognosis without valve replacement is poor (survival measured in a few years, with sudden death a risk), so symptomatic severe AS is an indication for prompt referral for intervention. In older patients, symptoms are often subtle (reduced exercise tolerance, fatigue) and wrongly attributed to age; ask what they have stopped doing.
- There is no drug treatment that slows aortic stenosis. Treat hypertension carefully (start low, avoid large drops in preload), and treat AF and coronary disease.
- Use vasodilators (nitrates, high-dose dihydropyridines) and diuretics cautiously in severe AS: they can cause hypotension and syncope.
- Advise asymptomatic patients with severe AS to avoid strenuous exertion and to report symptoms promptly.
- Dental care is important; endocarditis prophylaxis is not needed for native AS (Lesson 6).
3.3 TAVI or surgery? ★★★☆
The decision is made by a Heart Team (cardiologist, cardiac surgeon, imaging). The 2025 ESC/EACTS guideline recommends TAVI for patients aged 70 or older and surgical aortic valve replacement (SAVR) for younger, low-risk patients, taking into account anatomy (e.g. bicuspid valves), life expectancy and patient preference. Intervention may also be considered in asymptomatic severe high-gradient AS with preserved LV function when procedural risk is low.1,8 TAVI is Medicare-funded in Australia for patients assessed by a Heart Team at an accredited centre.
| Feature | TAVI | SAVR |
|---|---|---|
| Usual candidates | Aged ≥70; higher surgical risk; suitable femoral access | Younger (<70), low risk; complex anatomy; other surgery needed (e.g. CABG) |
| Recovery | Days | Weeks |
| Main risks | Pacemaker need, paravalvular leak, vascular injury, stroke | Surgical risk, AF, longer recovery |
| Antithrombotic after | Single antiplatelet (unless anticoagulation is needed for another reason) | Depends on valve type (section 8) |
| Driving (private) | Follow cardiologist advice and Austroads (usually a short non-driving period after the procedure) | |
4. Aortic regurgitation and bicuspid aortic valve ★★☆☆
Aortic regurgitation causes an early diastolic murmur at the left sternal edge (heard best sitting forward in expiration), a collapsing pulse and a wide pulse pressure. Causes include a bicuspid valve, aortic root dilatation (hypertension, Marfan syndrome), rheumatic disease and endocarditis. Acute AR (endocarditis, aortic dissection) is an emergency. Chronic severe AR is referred for surgery when symptoms develop or the LV dilates or its function falls.
A bicuspid aortic valve affects about 1–2% of people, more often men. It causes stenosis or regurgitation and is associated with aortopathy (ascending aorta dilatation, risk of dissection) and coarctation. Patients need periodic imaging of both valve and aorta, BP control, and echocardiographic screening of first-degree relatives.1
5. Mitral regurgitation and mitral valve prolapse ★★★☆
| Type | Cause | Treatment |
|---|---|---|
| Primary (degenerative) | The valve itself: mitral valve prolapse, flail leaflet, rheumatic disease, endocarditis | Severe and symptomatic, or LV dilating or dysfunction: surgical repair (preferred) or replacement; transcatheter edge-to-edge repair (TEER) if surgical risk is high |
| Secondary (functional) | The ventricle: dilated LV after MI or in cardiomyopathy, or atrial dilatation in AF | Heart failure therapy first (Lesson 4), CRT if indicated; TEER if severe MR persists despite optimal therapy |
Source: 2025 ESC/EACTS guideline.1,8 MR causes a pansystolic murmur at the apex radiating to the axilla. Acute severe MR (papillary muscle rupture after MI, chordal rupture, endocarditis) causes flash pulmonary oedema and is an emergency.
Mitral valve prolapse causes a mid-systolic click and late systolic murmur that start earlier with standing or Valsalva. Most people with MVP have a normal life expectancy; follow-up echo depends on the degree of regurgitation. Endocarditis prophylaxis is not recommended. Rarely, MVP with annular disjunction is associated with ventricular arrhythmias; refer if there is syncope or palpitations.
6. Mitral stenosis ★★★☆
Almost all mitral stenosis in younger patients is rheumatic. Severe calcification of the mitral annulus causes degenerative stenosis in older people. Signs: a loud S1, an opening snap and a low-pitched mid-diastolic rumble at the apex (best with the bell, patient on the left side), malar flush and AF. Symptoms are breathlessness, reduced exercise tolerance, haemoptysis and AF-related stroke; pregnancy, AF and infection precipitate decompensation.
- AF in mitral stenosis: anticoagulate with warfarin regardless of the CHA2DS2-VASc score; DOACs are not recommended in rheumatic MS (rivaroxaban was inferior in INVICTUS).4
- Rate control (beta-blocker) improves filling time; diuretics for congestion.
- Severe symptomatic MS with suitable anatomy: percutaneous balloon mitral commissurotomy; otherwise surgery.
- Women with significant MS need pre-pregnancy cardiology and obstetric medicine review: MS is poorly tolerated in pregnancy.
7. Right-sided valve disease ★☆☆☆
Tricuspid regurgitation is usually secondary to left heart disease, pulmonary hypertension or AF; primary causes include endocarditis in people who inject drugs, pacemaker leads and carcinoid syndrome. It causes a pansystolic murmur at the left lower sternal edge that increases with inspiration, large v waves in the JVP, a pulsatile liver and oedema. Transcatheter tricuspid therapies are now available for selected high-risk symptomatic patients.8 Pulmonary stenosis is usually congenital and found in childhood.
8. Prosthetic valves and anticoagulation ★★★★
8.1 Types of valve ★★☆☆
| Feature | Mechanical | Bioprosthetic (tissue), including TAVI |
|---|---|---|
| Durability | Lifelong | Degenerates over 10–20 years (faster in the young) |
| Anticoagulation | Lifelong warfarin | Usually 3 months after surgical mitral valve replacement, then antiplatelet; single antiplatelet after TAVI unless another indication |
| Usual candidate | Younger patient, able to manage warfarin, no plans for pregnancy | Older patients; women planning pregnancy; poor access to INR monitoring |
| On examination | Crisp metallic closing click | Normal sounds or soft flow murmur |
8.2 Anticoagulation ★★★★
| Situation | Recommendation |
|---|---|
| Mechanical aortic valve (bileaflet, no other risk factors) | Warfarin, target INR 2.5 (range 2.0–3.0) |
| Mechanical mitral valve, or aortic with risk factors (AF, previous embolism, LV dysfunction, older valve types) | Warfarin, target INR 3.0 (range 2.5–3.5) |
| Any mechanical valve | DOACs contraindicated (dabigatran caused more thrombosis and bleeding) |
| Rheumatic mitral stenosis with AF | Warfarin (INR 2.0–3.0); not a DOAC |
| AF with other valve disease (e.g. AS, MR) or a bioprosthetic valve | DOACs can be used |
| Interrupting warfarin (mechanical valve) for surgery | Bridging with heparin is usually needed for mitral or older valves; plan with the cardiologist. Most dental procedures: continue warfarin with local haemostasis |
Sources: Therapeutic Guidelines; 2025 ESC/EACTS guideline; INVICTUS.1,3,4 Check individual targets in the cardiologist’s letter; targets vary with valve type and patient factors.
- Fever: blood cultures before antibiotics (prosthetic valve endocarditis; Lesson 6).
- New breathlessness, embolic event or loss of the mechanical click: valve thrombosis or dysfunction; urgent echo and cardiology.
- Subtherapeutic INR with a mechanical valve: urgent dose adjustment and bridging advice.
- Pregnancy with a mechanical valve: very high risk; warfarin embryopathy (especially weeks 6–12) versus valve thrombosis on heparin; specialist pre-pregnancy planning and contraception.
8.3 Follow-up ★★★☆
- Baseline echo after valve replacement, then periodic echo (bioprosthetic valves more often after 5–10 years); clinical review yearly.
- Endocarditis prophylaxis for relevant dental procedures; regular dental care; an endocarditis card.
- INR monitoring (consider point-of-care or self-testing in suitable patients); warfarin interactions with antibiotics, azoles, amiodarone and many others.
- Haemolysis (anaemia, raised LDH) can occur with paravalvular leaks.
9. Acute rheumatic fever and rheumatic heart disease ★★★★
ARF is an autoimmune reaction to group A streptococcal (Strep A) infection of the throat or skin, typically 1–5 weeks later, most often in children aged 5–14. In Australia, it is concentrated in Aboriginal and Torres Strait Islander communities in northern and central Australia, and in Maori and Pacific Islander people and migrants from endemic countries. Repeated episodes damage the valves (mitral more than aortic), causing RHD.2
9.1 Diagnosing ARF (Australian Jones criteria) ★★★★
| Category | High-risk groups (First Nations, Maori, Pacific Islander, migrants from endemic areas, others at high risk) |
|---|---|
| Major | Carditis (including subclinical carditis on echo) Polyarthritis, aseptic monoarthritis or polyarthralgia Sydenham chorea Erythema marginatum Subcutaneous nodules |
| Minor | Fever ≥38°C Monoarthralgia ESR ≥30 mm/h or CRP ≥30 mg/L Prolonged PR interval or advanced conduction abnormality (if carditis is not a major criterion) |
| Evidence of Strep A | Raised or rising ASO or anti-DNase B titre, positive throat culture or rapid antigen/PCR test (not needed for chorea) |
| Initial episode | 2 major, or 1 major + 2 minor, plus evidence of Strep A |
| Recurrent episode (known ARF or RHD) | 2 major, or 1 major + 1 minor, or 3 minor, plus evidence of Strep A |
| Categories | Definite; probable (most likely ARF but criteria not fully met); possible (uncertain but cannot be excluded) |
Low-risk groups use stricter criteria (monoarthritis and polyarthralgia are minor, fever ≥38.5°C, ESR ≥60 mm/h).2 Every person with suspected ARF needs a full echocardiogram (handheld echo is not sufficient).
9.2 Managing ARF ★★★☆
- Admit to hospital for diagnosis, echo and education; notify (ARF and RHD are notifiable in several jurisdictions) and register with the state or territory RHD control program.
- Give BPG (first dose of secondary prophylaxis, which also eradicates Strep A).
- Arthritis: paracetamol first while awaiting diagnosis, then naproxen or ibuprofen (aspirin is less used); tramadol is no longer recommended.2
- Carditis with heart failure: heart failure treatment, specialist care; corticosteroids in selected severe carditis.
- Sydenham chorea: usually self-limiting; corticosteroids are now emphasised as potentially disease-modifying.
9.3 Secondary prophylaxis ★★★★
Regular BPG prevents recurrent ARF and progression of RHD; it is the single most important intervention. Only a minority of First Nations people with ARF or RHD receive all their prescribed injections, so adherence support is central.2
| Agent | Dose | Interval |
|---|---|---|
| Benzathine benzylpenicillin G (first line) | 1,200,000 units IM if ≥20 kg; 600,000 units if <20 kg | Every 28 days; every 21 days for selected people (breakthrough ARF despite full adherence, or high risk of harm from recurrence) |
| Phenoxymethylpenicillin (second line) | 250 mg orally twice daily | Only if IM BPG is not possible or is consistently declined (less effective) |
| Erythromycin (severe penicillin allergy) | 250 mg orally twice daily | Daily |
| Diagnosis | Minimum duration (whichever is longer), then reassess |
|---|---|
| Possible ARF, no cardiac involvement | 12 months, then reassess |
| Definite ARF, no cardiac involvement | 5 years after the most recent ARF episode, or until age 21 |
| Mild RHD (priority 3; stage B, or stage A with a history of ARF) | 10 years after the most recent ARF episode, or until age 21 |
| Moderate–severe regurgitation or any stenosis (priority 2; stage C) | 10 years after the most recent ARF episode, or until age 35 |
| RHD with complications (priority 1; stage D) | 10 years after the most recent ARF episode, or until age 40 |
Source: Australian ARF/RHD guideline 2025, Tables 10.2 and 10.3.2 Reduce injection pain with technique (e.g. buzzer devices, lidocaine-mixed preparations where available, distraction); consider oral prophylaxis for people at high risk of vasovagal syncope.
9.4 Primary prevention: sore throats and skin sores ★★★☆
In high-risk young people (e.g. First Nations children and young people in communities with high ARF rates), the 2025 guideline recommends empirical antibiotic treatment of sore throat without waiting for a swab, because only 20–40% of tonsillitis is caused by Strep A and missed infections cause ARF. Options include a single IM BPG injection or a full course of oral antibiotics; azithromycin is now a first-line oral option. Skin sores with pus or thick crust should also be treated with antibiotics, as skin Strep A infection also triggers ARF.2 Check doses in the guideline and Therapeutic Guidelines.
9.5 Living with RHD: pregnancy and long-term care ★★★☆
- Women of child-bearing age: effective contraception, pre-pregnancy echo and cardiology review, early booking in pregnancy with obstetric medicine; MS and mechanical valves carry the highest risk. BPG is safe in pregnancy and breastfeeding.
- Dental health: regular dental care and endocarditis prophylaxis (Lesson 6).
- Follow-up by priority: priority 1 (severe) needs echo and specialist review about every 3–6 months; priority 3 less often (follow the guideline’s table).
- Culturally safe care: Aboriginal health practitioners, family involvement, recall systems and outreach; the GP and clinic team hold the long-term relationship.
10. Old versus new guidance ★★★★
| Topic | Old teaching | Current |
|---|---|---|
| TAVI | Over 75 or inoperable | Preferred from age 70 (Heart Team) |
| Asymptomatic severe AS | Watchful waiting until symptoms | Intervention may be considered if low risk (high gradient, preserved LVEF) |
| AF with rheumatic MS | Any anticoagulant | Warfarin; no DOAC |
| Secondary MR | Medical therapy only | TEER if severe MR persists despite optimal heart failure therapy |
| RHD echo diagnosis | WHF 2012 (definite, borderline) | WHF 2023 stages A–D |
| Prophylaxis duration | Fixed ages for all | By priority/stage: age 21, 35 or 40 (minimum 5 or 10 years) |
| Sore throat (high-risk) | Swab first | Empirical treatment; azithromycin first-line oral option |
From the RACGP KFP 2025.1 public exam report5
- Answer technique: give only the number of answers requested and be specific (“benzathine benzylpenicillin 1,200,000 units IM every 28 days”, not “penicillin”). The published reports do not comment specifically on valve disease or rheumatic fever.
Other common traps
- Applying low-risk Jones criteria to a First Nations child (missing monoarthritis or polyarthralgia as major criteria, or using 38.5°C).
- Prescribing a DOAC for a mechanical valve or rheumatic mitral stenosis.
- Attributing exertional breathlessness or presyncope to age in a patient with known AS.
- Stopping BPG at age 21 in a patient with moderate or severe RHD.
11. Worked case (KFP style)
Tahlia Brown, aged 11 years, is an Aboriginal girl brought to a remote community clinic with 4 days of a painful, swollen right knee, then left ankle pain. She had skin sores on her legs 3 weeks ago. Temperature 38.3°C, pulse 110. The right knee is hot and swollen; the left ankle is painful but not swollen. You hear a soft pansystolic murmur at the apex. She weighs 34 kg.
Question 1. List up to four investigations that will help confirm the diagnosis.
Show answer
- ESR and CRP.
- Streptococcal serology: ASO and anti-DNase B titres (repeat in 10–14 days if not raised).
- ECG (PR interval or other conduction abnormality).
- Echocardiogram (comprehensive, via hospital).
Also accepted: throat swab or skin swab for Strep A; FBC; joint aspiration if septic arthritis is a concern; blood cultures. Scores zero: “bloods” without detail, rheumatoid factor, X-ray of the knee as the main test.
ESR 62 mm/h, CRP 48 mg/L, anti-DNase B raised, PR interval 220 ms. Echo shows moderate mitral regurgitation with rheumatic valve changes.
Question 2. What is the diagnosis? Write one answer.
Show answer
- Definite acute rheumatic fever with carditis (rheumatic heart disease: moderate mitral regurgitation).
Major: carditis, polyarthritis (knee arthritis plus ankle polyarthralgia). Minor: fever, raised ESR/CRP. Evidence of Strep A: raised anti-DNase B. (PR prolongation is not counted separately when carditis is a major criterion.)
Question 3. What secondary prophylaxis should she have? Include agent, dose, interval and minimum duration.
Show answer
- Benzathine benzylpenicillin G 1,200,000 units IM every 28 days, for at least 10 years after the most recent ARF episode or until age 35 (whichever is longer), then reassess.
Moderate MR is priority 2 (stage C) disease. Scores zero: oral penicillin as first choice, “until 21”, “600,000 units” (she weighs over 20 kg).
Question 4. List up to three other long-term actions for her care.
Show answer
- Notify and register her with the RHD control program (recall for injections and echo).
- Dental review and ongoing dental care; endocarditis prophylaxis for relevant dental procedures.
- Regular echo and specialist review; education for her and her family; contraception and pre-pregnancy planning when older.
12. Self-check questions
These questions are written at or above AKT difficulty. Every option is plausible and the options are deliberately similar. Commit to an answer before revealing the explanation.
Leonard Fitzgerald, aged 78 years, has had two episodes of light-headedness while walking up a hill. He has a harsh grade 3/6 ejection systolic murmur loudest at the right upper sternal edge, radiating to both carotids. The murmur becomes softer during the strain phase of the Valsalva manoeuvre. His carotid pulse is slow-rising and of low volume, and the second heart sound is soft and single. The ECG shows left ventricular hypertrophy.
What is the MOST likely diagnosis?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. Calcific aortic stenosis
Feedback: This question requires candidates to integrate murmur, pulse, heart sounds and a manoeuvre. An ejection systolic murmur radiating to the carotids, a slow-rising low-volume pulse, a soft single S2, LVH and exertional presyncope in an older man indicate severe calcific aortic stenosis. The murmur softens with Valsalva (less preload), which is the opposite of HCM.
- Aortic valve sclerosis: a similar murmur but a normal pulse and normal A2, and no symptoms or LVH.
- Chronic aortic regurgitation: early diastolic murmur and a collapsing pulse.
- Mitral valve prolapse: mid-systolic click and late systolic murmur at the apex, longer with Valsalva.
- Obstructive cardiomyopathy: murmur louder with Valsalva; brisk, not slow-rising, pulse.
- Primary mitral regurgitation: pansystolic murmur at the apex radiating to the axilla.
- Pulmonary valve stenosis: left upper sternal edge, louder on inspiration, usually found in childhood.
- Ventricular septal defect: pansystolic murmur at the left lower sternal edge; does not cause a slow-rising pulse.
Reference: ESC/EACTS valvular heart disease guideline 2025.
Edith Morrison, aged 81 years, has aortic stenosis. An echo 3 years ago showed moderate AS. She now becomes breathless walking to her letterbox, which she puts down to age. She lives independently and is cognitively intact. A new echo shows peak velocity 4.4 m/s, mean gradient 48 mmHg, valve area 0.8 cm² and LVEF 60%.
What is the MOST appropriate next step?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: C. Refer to the Heart Team for valve intervention
Feedback: This question requires candidates to recognise symptomatic severe AS (all three echo criteria met) and act on it. Exertional breathlessness in severe AS is a symptom of the valve, not of age, and carries a poor prognosis without intervention. At 81, with good function, TAVI is likely to be offered.
- Advise rest; reassess urgently if syncope occurs: waiting for syncope risks sudden death.
- Exercise stress test to confirm her symptoms: exercise testing is for apparently asymptomatic severe AS; it is contraindicated when symptoms are present.
- Repeat the echocardiogram in 6 months’ time: appropriate surveillance only for asymptomatic severe AS.
- Start furosemide and review again in 4 weeks: diuretics do not treat AS and can cause hypotension.
Reference: ESC/EACTS valvular heart disease guideline 2025.
Grace Liang, aged 52 years, had a mechanical mitral valve replacement for rheumatic mitral stenosis 10 years ago. She is in sinus rhythm and has no other risk factors. She has read about newer anticoagulants that need no blood tests and asks to change from warfarin.
What is the MOST appropriate anticoagulation plan?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. Continue warfarin, target INR 3.0 (2.5–3.5)
Feedback: This question requires candidates to combine two rules: DOACs are contraindicated with mechanical valves, and mechanical mitral valves need a higher INR target than bileaflet aortic valves because of higher thrombotic risk. Offer INR self-testing or point-of-care monitoring to make warfarin easier.
- Continue warfarin, target INR 2.5 (2.0–3.0): the target for a bileaflet mechanical aortic valve without risk factors.
- Switch to apixaban 5 mg twice daily: DOACs are contraindicated with mechanical valves.
- Switch to dabigatran 150 mg twice daily: increased valve thrombosis and bleeding in the RE-ALIGN trial.
- Switch to rivaroxaban 20 mg once daily: contraindicated; also inferior in rheumatic heart disease with AF.
Reference: Therapeutic Guidelines: Cardiovascular; ESC/EACTS guideline 2025.
Kobe Martin, aged 12 years, an Aboriginal boy in a remote Kimberley community, has a hot, swollen left knee and fever of 38.2°C for 3 days. Knee aspirate shows no organisms and is culture-negative. ESR 48 mm/h, CRP 35 mg/L, ASO and anti-DNase B are raised. ECG: PR interval 160 ms (normal for age). A comprehensive echo is normal. No other joints, rash, nodules or chorea.
What is the MOST appropriate diagnostic classification?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: A. Definite ARF: 1 major plus 2 minor criteria
Feedback: This question requires candidates to apply the high-risk Australian criteria. In high-risk groups, aseptic monoarthritis is a major criterion; fever ≥38°C and ESR/CRP ≥30 are two minor criteria; raised streptococcal titres provide the required evidence of Strep A. One major plus two minor is definite ARF. He needs BPG and registration even with a normal echo.
- Not ARF: post-streptococcal reactive arthritis: in high-risk groups, this label should not be used when Jones criteria are met; it risks withholding prophylaxis.
- Not ARF: septic arthritis until proven otherwise: the aspirate is sterile; septic arthritis has been excluded.
- Possible ARF: needs a second major criterion: 1 major + 2 minor is sufficient for definite ARF.
- Probable ARF: monoarthritis is only a minor one: the low-risk criteria; he belongs to a high-risk group.
Reference: Australian ARF/RHD guideline 2025.
Shanice Kelly, aged 15 years, is a Torres Strait Islander girl with ARF diagnosed this year. Her echo shows moderate mitral regurgitation and mild aortic regurgitation, with no complications (WHF stage C, priority 2). She weighs 52 kg and is starting monthly BPG.
What is the MOST appropriate minimum duration of secondary prophylaxis?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. 10 years after last ARF or to age 35, whichever longer
Feedback: This question requires candidates to match RHD severity to prophylaxis duration. Moderate regurgitation is priority 2 (stage C), which needs a minimum of 10 years after the most recent ARF or until age 35, whichever is longer, then reassessment.
- 10 years after last ARF or to age 21, whichever longer: mild RHD (priority 3).
- 10 years after last ARF or to age 40, whichever longer: RHD with complications (priority 1, stage D).
- 5 years after last ARF or to age 21, whichever longer: ARF without cardiac involvement.
- Lifelong, with no planned review of the need: the guideline sets minimum durations and then reassessment.
Reference: Australian ARF/RHD guideline 2025, Table 10.3.
Jayden Wilson, aged 17 years, weighs 64 kg and has mild RHD. Clinic records show he has received every 4-weekly BPG injection on time for 3 years. He has now had a confirmed recurrence of ARF, with a new increase in mitral regurgitation. He has no penicillin allergy.
What is the MOST appropriate change to his secondary prophylaxis?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: A. BPG 1,200,000 units every 21 days
Feedback: This question requires candidates to manage breakthrough ARF despite documented full adherence. The guideline allows shortening the interval to every 21 days in this situation. The dose stays at 1,200,000 units because he weighs 20 kg or more. His duration of prophylaxis also restarts from this most recent episode.
- BPG 1,200,000 units every 28 days: his current regimen, which has failed despite adherence.
- BPG 2,400,000 units every 28 days: not a recommended prophylaxis dose.
- BPG 600,000 units every 21 days: the dose for people under 20 kg.
- Phenoxymethylpenicillin 250 mg bd: oral prophylaxis is less effective and second line.
Reference: Australian ARF/RHD guideline 2025, Table 10.2.
Mia Roberts, aged 9 years, is an Aboriginal girl in a remote Northern Territory community with high rates of ARF. She has had a sore throat and fever for 2 days. She has no cough. There are no skin sores. She has no penicillin allergy. Throat swabs are sent to a regional laboratory with results in 3–4 days.
What is the MOST appropriate management?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: C. Single IM benzathine benzylpenicillin
Feedback: This question requires candidates to apply primary prevention of ARF in a high-risk child. The 2025 guideline recommends empirical treatment of sore throat in high-risk young people without waiting for results. A single IM BPG dose guarantees completion; a full course of an appropriate oral antibiotic (with azithromycin now a first-line oral option) is the alternative.
- Phenoxymethylpenicillin for 5 days: oral penicillin requires a 10-day course to eradicate Strep A.
- Rapid antigen test; treat if positive: a negative test should not delay treatment in a high-risk child.
- Symptomatic care; no antibiotics needed: appropriate for low-risk children, not high-risk communities.
- Throat swab; treat only if Strep A grows: waiting 3–4 days risks missing treatment altogether.
Reference: Australian ARF/RHD guideline 2025.
Daniel Hughes, aged 40 years, attends because his 44-year-old brother has just had surgery for a bicuspid aortic valve with ascending aortic dilatation. Daniel is well, BP 132/82 mmHg, and you hear no murmur. He asks whether he needs any tests.
What is the MOST appropriate investigation?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: E. Transthoracic echocardiogram
Feedback: This question requires candidates to know that bicuspid aortic valve and its aortopathy are familial. First-degree relatives should be screened with transthoracic echocardiography, which shows the valve and the aortic root and ascending aorta. A normal examination does not exclude a bicuspid valve or a dilated aorta.
- 12-lead ECG and chest X-ray: insensitive for both the valve and early aortic dilatation.
- Cardiac magnetic resonance: used if echo windows are poor or the aorta needs fuller imaging, not first.
- CT aortic angiography: for aortic dilatation found on echo or poorly seen; involves radiation and contrast.
- Genetic panel testing: no single gene explains most bicuspid valves; testing is reserved for syndromic or familial aortopathy under specialists.
Reference: ESC/EACTS valvular heart disease guideline 2025.
Got this wrong? Re-read 4. Aortic regurgitation and bicuspid aortic valve →
Oliver Chen, aged 5 years, is brought for a preschool check. You hear a grade 2/6 low-pitched, vibratory, musical systolic murmur at the left lower sternal edge, louder lying down and softer when he sits up. Heart sounds are normal, with physiological splitting of S2. Femoral pulses are normal, he is growing well and he is active. He has no fever. His family has no history of heart disease. He is not from a population at high risk of RHD.
What is the MOST appropriate management?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. Reassure; no investigation is needed
Feedback: This question requires candidates to recognise a Still’s (innocent) murmur and show restraint. A soft, vibratory, musical systolic murmur that varies with posture, with normal heart sounds and pulses, in a well, thriving child, is innocent. Explain to the family that it is a normal flow sound and that it may be heard again during illnesses.
- Arrange ECG and chest X-ray first: low yield and do not change management.
- Refer for echocardiogram within 4 weeks: for murmurs with pathological features or in high-risk populations.
- Refer to a paediatric cardiologist urgently: for symptoms, cyanosis, abnormal pulses or heart failure.
- Repeat the examination in 2 weeks’ time: relevant if a murmur is heard during fever; he is afebrile and the features are classic.
Reference: Royal Children’s Hospital Melbourne clinical practice guideline (heart murmurs).
Leanne Mitchell, aged 38 years, has rheumatic heart disease with moderate mitral stenosis (valve area 1.3 cm²). She presents with palpitations and is found to be in atrial fibrillation. She has no hypertension, diabetes, heart failure or previous stroke. eGFR is 95 mL/min/1.73 m2. She uses a copper IUD for contraception.
What is the MOST appropriate antithrombotic therapy?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: E. Warfarin, target INR 2.0–3.0
Feedback: This question requires candidates to know that AF with rheumatic mitral stenosis carries a high stroke risk regardless of the CHA2DS2-VASc score, and that a DOAC is not appropriate. In INVICTUS, rivaroxaban led to more cardiovascular events and deaths than warfarin in rheumatic heart disease with AF. Warfarin is also compatible with her contraception (warfarin is teratogenic, so contraception matters).
- Apixaban 5 mg twice daily: DOACs are not recommended in rheumatic mitral stenosis.
- Aspirin 100 mg once daily: ineffective for stroke prevention in AF.
- No anticoagulant; CHA2DS2-VASc 1: the score does not apply to AF with mitral stenosis.
- Rivaroxaban 20 mg once daily: inferior to warfarin in INVICTUS.
Reference: Connolly SJ, et al. INVICTUS. NEJM 2022; ESC/EACTS guideline 2025.
Self-check score: / 10
Sure but wrong:
Any “sure but wrong” answer is your highest exam risk. Re-read those sections first, then use the flashcards at the end of the lesson. Your selections are not saved; the score resets when you leave the page.
Tick each one you can do without notes. Anything left unticked is your revision list.
- Not yet? Re-read section 2.1 →
- Not yet? Re-read section 2.2 →
- Not yet? Re-read section 3.1 →
- Not yet? Re-read section 3.3 →
- Not yet? Re-read section 8.2 →
- Not yet? Re-read section 9.1 →
- Not yet? Re-read section 9.3 →
- Not yet? Re-read section 9.4 →
Ready on of 8.
13. Key takeaways
- Murmurs: any diastolic murmur, grade ≥3/6, thrill, symptoms or abnormal pulses → echo. Any murmur in a high-risk RHD population → echo.
- Manoeuvres: Valsalva and standing soften most murmurs but make HCM louder and MVP longer.
- Severe AS: Vmax ≥4 m/s, mean gradient ≥40 mmHg, AVA <1.0 cm². Symptoms (breathlessness, angina, syncope) → prompt referral.
- TAVI: preferred from age 70 (2025 ESC/EACTS); asymptomatic severe AS may be treated if low risk.
- Echo surveillance in AS: mild every 3–5 years, moderate every 1–2 years, severe every 6–12 months.
- Bicuspid valve: aortopathy; screen first-degree relatives with echo.
- Mechanical valves: warfarin for life; INR 2.5 (aortic bileaflet), 3.0 (mitral or risk factors); DOACs contraindicated.
- Rheumatic MS with AF: warfarin regardless of CHA2DS2-VASc; not a DOAC.
- ARF (high-risk): monoarthritis and polyarthralgia are major; fever ≥38°C; ESR or CRP ≥30; initial = 2 major or 1 major + 2 minor, plus Strep A evidence.
- BPG: 1,200,000 units (≥20 kg) or 600,000 units (<20 kg) IM every 28 days (21 days for breakthrough).
- Duration: ARF only: 5 years/age 21; mild RHD: 10 years/age 21; moderate: 10 years/age 35; severe: 10 years/age 40 (whichever longer).
- Primary prevention: empirical treatment of sore throat in high-risk young people; treat purulent or crusted skin sores.
Your revision plan
| When | What to do |
|---|---|
| Today | Finish the lesson, both question sets and the readiness checklist. Note every “sure but wrong” answer. |
| Day 3 | Do this lesson’s 10 flashcards again (end of this lesson). Re-read every section you marked “Not yet”. |
| Day 7 | Redo the self-check questions without looking at the lesson. Aim for 8/10 with no “sure but wrong”. |
| Day 21 | Do the cardiovascular chapter flashcard deck, then one timed block of mixed questions at exam pace. |
| Week before the exam | Re-read the key takeaways, Tables 8 and 9 and the old-notes box. Do the chapter flashcard deck once more. |
Your next step
Use your scores from the cold-start check and the self-check questions to choose your next step.
Flashcards: 10 high-yield recall cards
Finish the lesson by testing your recall. Say the answer out loud before you tap the card to flip it, then mark “I knew this” only if you were fully right without looking. Repeat the cards on day 3 and day 21, and use the cardiovascular chapter deck for later reviews.
14. References and recommended reading
References
- Praz F, Borger MA, et al. 2025 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2025.
- RHDAustralia (ARF/RHD writing group). The 2025 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3.2 edition). csanz.edu.au (accessed 10 Nov 2026).
- Therapeutic Guidelines. Cardiovascular (current version): valvular heart disease; anticoagulation. Melbourne: Therapeutic Guidelines Limited. tg.org.au (accessed 10 Nov 2026).
- Connolly SJ, Karthikeyan G, Ntsekhe M, et al (INVICTUS). Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. N Engl J Med 2022;387:978–88.
- The Royal Australian College of General Practitioners. KFP 2025.1 public exam report. Melbourne: RACGP; 2025. racgp.org.au (accessed 10 Nov 2026).
- The Royal Australian College of General Practitioners. AKT and KFP: general exam delivery information. racgp.org.au (accessed 10 Nov 2026).
- Australian Dental Association. Endocarditis prophylaxis for dental procedures (2026), via ADA WA. adawa.com.au (accessed 10 Nov 2026).
- Sticchi A. Key updates in valvular heart disease management: insights from the 2025 ESC/EACTS guidelines. PCRonline; 2025. pcronline.com (accessed 10 Nov 2026).
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Circulation 2021;143:e72–227.
Recommended reading for RACGP fellowship candidates
- 2025 Australian ARF/RHD guideline — Jones criteria, prophylaxis tables, primary prevention; the most examinable Australian-specific valve content.
- Therapeutic Guidelines: Cardiovascular — valve disease, INR targets and anticoagulation.
- 2025 ESC/EACTS valvular heart disease guideline — AS, MR and intervention thresholds.
- Royal Children’s Hospital clinical practice guidelines — heart murmurs in children.
- NACCHO–RACGP National Guide — ARF and RHD prevention in Aboriginal and Torres Strait Islander people.
- Murtagh’s General Practice; RACGP check and AJGP; RACGP curriculum: cardiovascular health; Aboriginal and Torres Strait Islander health.
Version history
| Version | Date | Changes |
|---|---|---|
| 2026–27 (v1.0) | 10 Nov 2026 | First edition, with engagement layer, study-priority stars and end-of-lesson flashcards. Based on the 2025 Australian ARF/RHD guideline, 2025 ESC/EACTS valvular heart disease guideline, Therapeutic Guidelines and INVICTUS. |
© GP Institute of Australia. For educational use by enrolled candidates only; not for redistribution. This lesson summarises Australian guidelines for exam preparation and does not replace current clinical guidelines or clinical judgement. Always check doses in current Therapeutic Guidelines, AMH and the ARF/RHD guideline.